"10.1371_journal.pone.0060691","plos one","2013-04-03T00:00:00Z","Géraldine H Petit; Elijahu Berkovich; Mark Hickery; Pekka Kallunki; Karina Fog; Cheryl Fitzer-Attas; Patrik Brundin","Neuronal Survival Unit, Wallenberg Neuroscience Center, Department of Experimental Medical Science, BMC B11, Lund University, Lund, Sweden; Teva Pharmaceutical Industries Ltd., Global Innovative Products, Petach-Tikva, Israel; H. Lundbeck A/S, Neurology, Copenhagen, Denmark; H. Lundbeck A/S, Neurodegeneration-1, Copenhagen, Denmark; Van Andel Research Institute, Center for Neurodegenerative Science, Grand Rapids, Michigan, United States of America","Conceived and designed the experiments: GHP EB MH PK KF CFA PB. Performed the experiments: GHP. Analyzed the data: GHP. Contributed reagents/materials/analysis tools: GHP EB PK KF CFA PB. Wrote the paper: GHP EB MH PK KF CFA PB.","Teva Pharmaceutical Industries Ltd and H.Lundbeck A/S, which market rasagiline, contributed to the funding of this study. The authors EB and CFA work for Teva Pharmaceutical Industries Ltd. The authors MH, PK and KF work for H.Lundbeck A/S. PB has received speaking honoraria from and provided consulting services to Teva Pharmaceutical Industries Ltd and H.Lundbeck A/S. Teva Pharmaceutical Industries Ltd. covered the costs of GHP to attend the MDS congress (Toronto 2011). The use of rasagiline for the treatment of olfactory dysfunction is covered by patent number US 2012/0029087 A1. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.",NA,NA,NA,"2013","04","Géraldine H Petit","GHP",7,TRUE,7,1,1,7,TRUE,TRUE,FALSE,0,NA,FALSE
